跳至主要内容
临床试验/NCT00802685
NCT00802685终止不适用

Timing of PDA Closure and Respiratory Outcome in Premature Infants

University of Miami1 个研究点 分布在 1 个国家目标入组 105 人开始时间: 2007年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
终止
入组人数
105
试验地点
1
主要终点
Days Spent on Supplemental Oxygen During the First 28 Days.

研究概览

简要总结

The investigators propose the present study with the following aims:

  • to determine whether early patent ductus arteriosus (PDA) treatment with ibuprofen treatment at the onset of clinical symptoms is superior to late ibuprofen treatment only when symptoms of a hemodynamically significant PDA are present in the evolution of bronchopulmonary dysplasia (BPD) defined as duration of supplemental oxygen exposure during the first 28 days
  • to determine whether early PDA treatment with ibuprofen will be superior to late treatment with ibuprofen in efficacy of PDA closure, need for rescue therapy, need for PDA ligation and incidence of major complications of prematurity.

Hypothesis: Early pharmacologic closure of PDA with ibuprofen will improve respiratory course and reduce BPD as reflected by a reduction in duration of supplemental oxygen during the first 28 days of age vs. late pharmacologic treatment with ibuprofen.

Outcome variables: The primary outcome of this study is the number of days spent on supplemental oxygen by each infant during the first 28 days.

Other outcomes to be determined between groups include:

  • Mortality
  • Other respiratory variables: total days on supplemental oxygen, days on mechanical ventilation, oxygen dependence at 36 weeks post menstrual age, age at final extubation.
  • Other respiratory complications: pneumothorax, pulmonary interstitial emphysema, need for high frequency ventilation, pulmonary hypertension
  • Efficacy of PDA closure: number of courses of medication required, need for ligation
  • Other neonatal complications: intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), retinopathy of prematurity (ROP), necrotizing enterocolitis (NEC), intestinal perforation, sepsis, renal dysfunction (oliguria, elevated creatinine)
  • Time to achieving full enteral feedings, time to regain birth weight, weight at discharge.
  • Length of hospital stay

详细描述

Study terminated when intravenous (IV) ibuprofen withdrawn for both clinical and research use.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
1 Day 至 14 Days(Child)
性别
All
接受健康志愿者

入选标准

  • Inborn patients at JHS hospitals (admitted to the NICU at JMH within the first 72 hrs of age
  • BW 500-1250 grams
  • 23-32 wks gestational age
  • > 1d but < 14d of age.

排除标准

  • Major congenital malformations
  • Proven sepsis (positive blood culture)
  • Contraindications to the use of Ibuprofen or Indomethacin
  • Terminal condition, not expected to survive beyond 48 h
  • Infants born excessively SGA(3 S.D. below the mean for GA)
  • Infants with initial PDA presentation that is hemodynamically significant

研究组 & 干预措施

early ibuprofen

Experimental

Drug: Early ibuprofen

IBUPROFEN DOSING SCHEDULE: At the diagnosis of PDA, infants randomized to "early treatment" will receive blinded ibuprofen initial dose 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy will be blinded. This group will then be eligible to receive unblinded, open label ibuprofen for a hemodynamically significant PDA include: SIGNS OF PDA + Presence of significant pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (not due to something other than PDA) defined as at least two of the following respirator settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV.

干预措施: Early ibuprofen (Drug)

Late Ibuprofen expectant group (placebo)

Other

Late ibuprofen expectant group (placebo): Ibuprofen schedule: At PDA diagnosis, infants randomized to "late expectant group" will receive blinded placebo. If hemo-dynamically significant PDA develops, infants now receive open label ibuprofen, initial dose of 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA: Signs of PDA + pulmonary hemorrhage alone or Signs of PDA + Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following respirator settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV. Infants who had received placebo will ibuprofen for the first time (thus, "late" ibuprofen or expectant).

干预措施: Late ibuprofen expectant group (placebo) (Other)

结局指标

主要结局

Days Spent on Supplemental Oxygen During the First 28 Days.

时间窗: 28 days of life

次要结局

  • Number of Participants on Oxygen at 36 Weeks Postmenstrual Age(at 36 weeks postmenstrual age)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ilene R.S. Sosenko, M.D.

Professor of Pediatrics

University of Miami

研究点 (1)

Loading locations...

相似试验